 |
0 Diseases |  |
24 Trials |
|
24 Trials |  |
921 News |  |
| «12...891011121314151617181920» |
- ||| semaglutide oral (NN9924) / Novo Nordisk
Resumen seguridad semaglutide oral en #PIONEER6 #ADA2019 (Twitter) - Jun 11, 2019
- |||| semaglutide oral (NN9924) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical: #ADA2019 Pioneer-6 #CVOT showed 21% RR reduction for MACE with oral #semaglutide vs usual care. Driven by significant decrease in CV mortality. Surprising in short trial but good news for #patients with #T2DM. #nejm (Twitter) - Jun 11, 2019
- ||| semaglutide oral (NN9924) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Oral semaglutide vs empagliflozin. Choices for step 1 or step 2 in managing type 2. #ADA2019 (Twitter) - Jun 11, 2019
- |||| semaglutide oral (NN9924) / Novo Nordisk
Clinical: Summary of oral semaglutide compared to placebo. Look at the nausea data though. #ADA2019 @ADA_DiabetesPro (Twitter) - Jun 11, 2019
- |||| semaglutide oral (NN9924) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Exciting last session at #ADA2019. - oral #semaglutide in the PIONEER program. Including the #CVOT #PIONEER-6! @rpratleyMD presenting comparator studies. (Twitter) - Jun 11, 2019
- ||||| semaglutide oral (NN9924) / Novo Nordisk
Preclinical: Some additional perspectives coming Tuesday, #ADA2019 the oral semaglutide program, and our latest thoughts revealing new insights into mechanisms of GLP-1 action in mice (Twitter) - Jun 10, 2019
- || semaglutide oral (NN9924) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
PIONEER: Oral semaglutide proves superior to empagliflozin, noninferior to liraglutide for lowering HbA1c June 9, 2019 (Twitter) - Jun 10, 2019
- |||| semaglutide oral (NN9924) / Novo Nordisk
Clinical: Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial https://t.co/vGVoDEK0Az (Twitter) - Jun 8, 2019
- | Victoza (liraglutide) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Review, Journal: Centrally Acting Agents for Obesity: Past, Present, and Future. (Pubmed Central) - May 17, 2019
Another potential new pharmacotherapy, setmelanotide, is a melanocortin-4 receptor agonist, which is still in an early stage of development. As our understanding of the communication between the CNS, gut, adipose tissue, and other organs evolves, it is anticipated that obesity drug development will move toward new centrally acting combinations and then to drugs acting on peripheral target tissues.
- ||| semaglutide oral (NN9924) / Novo Nordisk
Yes, absolutely. Until oral semaglutide becomes available. Pills are easier than shots. The GLP1 agonists make you feel like you have the flu. (Twitter) - May 8, 2019
- ||| semaglutide oral (NN9924) / Novo Nordisk
Two reasons: enthusiasm about SGLT2i's (justified, no question) plus the lack of an oral GLP1-RA. However, oral semaglutide is coming, so that will change the discourse a little. To me, the importance is to tailor the therapy to the phenotype. Athero: GLP; Heart muscle: SGLT2 (Twitter) - May 8, 2019
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: PIONEER 7: Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. (clinicaltrials.gov) - Apr 30, 2019
P3, N=504, Completed, Sponsor: Novo Nordisk A/S
As our understanding of the communication between the CNS, gut, adipose tissue, and other organs evolves, it is anticipated that obesity drug development will move toward new centrally acting combinations and then to drugs acting on peripheral target tissues. Active, not recruiting --> Completed
- ||||| semaglutide oral (NN9924) / Novo Nordisk
Pricing: Thankfully, I am not in charge of drug pricing decisions. Here is a summary of the oral semaglutide PIONEER P3 program #diabetes (Twitter) - Apr 26, 2019
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P2/3 trial: TEAL: Treating PCOS With Semaglutide vs Active Lifestyle Intervention (clinicaltrials.gov) - Apr 17, 2019
P2/3, N=50, Not yet recruiting, Sponsor: University of Colorado, Denver
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial: SOUL: A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (clinicaltrials.gov) - Apr 16, 2019
P3, N=9642, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||| semaglutide oral (NN9924) / Novo Nordisk
Clinical: Now in @JACCJournals: Despite established CVD in >1/3 of pts prescribed GLP1-RA at 2 large academic centers, we found that cardiologists had limited engagement in prescription Will this change in light of the PIONEER (oral semaglutide) trial program? @DLBHATTMD @mvaduganathan (Twitter) - Mar 25, 2019
- ||||| semaglutide oral (NN9924) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Clinical: Consistent with national market share data, we observed recent expanded use of dulaglutide (Trulicity), which now accounts for most new GLP-1RA Rx in our health system. Will oral semaglutide & adapted patient-friendly injection designs be enough to change prescriber behavior? (Twitter) - Mar 25, 2019
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men (clinicaltrials.gov) - Dec 10, 2018
P1, N=105, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: SUSTAIN 8: Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Dec 6, 2018
P3, N=788, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Enrollment change: A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Oct 31, 2018
P1, N=15, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=22 --> 15
- | Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men (clinicaltrials.gov) - Oct 29, 2018
P1, N=104, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed | N=22 --> 15 Recruiting --> Active, not recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: PIONEER 6: A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Oct 24, 2018
P3, N=3183, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Review, Journal: Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon. (Pubmed Central) - Oct 4, 2018
This review focuses on anti-obesity drugs in the pipeline including centrally acting agents (setmelanotide, neuropeptide Y antagonist [velneperit], zonisamide-bupropion [Empatic], cannabinoid type-1 receptor blockers), gut hormones and incretin targets (new glucagon-like-peptide-1 [GLP-1] analogues [semaglutide and oral equivalents], amylin mimetics [davalintide, dual amylin and calcitonin receptor agonists], dual action GLP-1/glucagon receptor agonists [oxyntomodulin], triple agonists [tri-agonist 1706], peptide YY, leptin analogues [combination pramlintide-metreleptin]), and other novel targets (methionine aminopeptidase 2 inhibitor [beloranib], lipase inhibitor [cetilistat], triple monoamine reuptake inhibitor [tesofensine], fibroblast growth factor 21), including anti-obesity vaccines (ghrelin, somatostatin, adenovirus36). With these new drugs in development, anti-obesity therapeutics have potential to vastly expand allowing better treatment options and personalized approach to obesity care.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: PIONEER 8: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (clinicaltrials.gov) - Sep 10, 2018
P3, N=731, Completed, Sponsor: Novo Nordisk A/S
With these new drugs in development, anti-obesity therapeutics have potential to vastly expand allowing better treatment options and personalized approach to obesity care. Active, not recruiting --> Completed
- | Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men (clinicaltrials.gov) - Aug 27, 2018
P1, N=104, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men (clinicaltrials.gov) - Aug 19, 2018
P1, N=104, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Monotherapy: PIONEER 9: Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Aug 17, 2018
P3, N=243, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Combination therapy: PIONEER 10: Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jul 17, 2018
P3, N=458, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects (clinicaltrials.gov) - Jul 16, 2018
P1, N=21, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects (clinicaltrials.gov) - Jul 6, 2018
P1, N=21, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: PIONEER 5: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment (clinicaltrials.gov) - Jun 26, 2018
P3, N=324, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: PIONEER 3: Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Apr 25, 2018
P3, N=1864, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: PIONEER 4: Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Apr 20, 2018
P3, N=690, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: PIONEER 2: Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Mar 26, 2018
P3, N=827, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects (clinicaltrials.gov) - Mar 20, 2018
P1, N=21, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects (clinicaltrials.gov) - Mar 14, 2018
P1, N=21, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: PIONEER 7: Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. (clinicaltrials.gov) - Mar 5, 2018
P3, N=500, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2018 --> Feb 2018
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: PIONEER 8: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (clinicaltrials.gov) - Mar 3, 2018
P3, N=720, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Feb 2018 --> Feb 2018 Trial primary completion date: Jan 2018 --> Jan 2018
- |||| Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date, Monotherapy: PIONEER 9: Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Mar 3, 2018
P3, N=240, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jan 2018 --> Jan 2018 Trial primary completion date: Jan 2018 --> Jan 2018
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: PIONEER 1: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (clinicaltrials.gov) - Mar 3, 2018
P3, N=703, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jan 2018 --> Jan 2018 Trial primary completion date: Oct 2017 --> Oct 2017
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed, Trial primary completion date: A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Feb 8, 2018
P1, N=22, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Oct 2017 --> Oct 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> Nov 2018
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: PIONEER 6: A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Dec 22, 2017
P3, N=3176, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> Nov 2018 Trial primary completion date: Apr 2018 --> Oct 2018
- |||| Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date, Monotherapy: PIONEER 9: Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Dec 21, 2017
P3, N=240, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Apr 2018 --> Oct 2018 Trial primary completion date: Aug 2018 --> Jan 2018
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: PIONEER 1: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (clinicaltrials.gov) - Dec 13, 2017
P3, N=704, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Aug 2018 --> Jan 2018 Active, not recruiting --> Completed
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: PIONEER 5: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment (clinicaltrials.gov) - Dec 8, 2017
P3, N=324, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Trial primary completion date: Jan 2018 --> May 2018
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes. (clinicaltrials.gov) - Nov 28, 2017
P1, N=55, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jan 2018 --> May 2018 Active, not recruiting --> Completed
- || Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes. (clinicaltrials.gov) - Oct 30, 2017
P1, N=52, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: PIONEER 5: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment (clinicaltrials.gov) - Oct 26, 2017
P3, N=324, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: SUSTAIN 8: Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Oct 26, 2017
P3, N=784, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: PIONEER 6: A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Sep 14, 2017
P3, N=3176, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting